Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abuse Potential of Rapastinel in Recreational Polydrug Users
NCT03799900Phase 1Completed
- Sponsor
- Allergan
- Start
- Nov 2018
- Primary completion
- Mar 2019
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of rapastinel in major depressive disorder (MDD) (12 arms), sponsored by Allergan. Primary endpoint: Maximum effect (Emax) for 'At this Moment' Drug Liking visual analog scale (VAS). Started Nov 2018; status: completed.
02
Drugs
rapastinel
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03799900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03799900.